<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alejandro A Rabinstein, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">José Biller, MD, FACP, FAAN, FAHA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Unruptured intracranial aneurysms are detected in up to 2 to 3 percent of older adults who undergo high-quality noninvasive intracranial arterial imaging (eg, magnetic resonance angiography, computed tomographic angiography). Subarachnoid hemorrhage from a ruptured intracranial aneurysm is associated with a short-term mortality of 40 percent, with one-half of survivors sustaining permanent neurologic injury. Thus, detection of an asymptomatic unruptured aneurysm creates a management dilemma in patients who have indications for antithrombotic therapy. (See  <a class="medical medical_review" href="/z/d/html/1132.html" rel="external">"Unruptured intracranial aneurysms"</a>.)</p><p>This topic review will discuss issues related to anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm.</p><p class="headingAnchor" id="H2"><span class="h1">THEORETICAL EFFECTS OF ANTITHROMBOTIC MEDICATION USE</span><span class="headingEndMark"> — </span>Rates of rupture for previously detected unruptured aneurysms vary according to their size (ie, there is a greater risk of rupture in larger aneurysms), specific location (eg, higher rates of rupture with posterior circulation aneurysms) [<a href="#rid1">1</a>], as well as history of prior subarachnoid hemorrhage from a separate aneurysm [<a href="#rid2">2</a>]. This subject is reviewed in depth separately. (See  <a class="medical medical_review" href="/z/d/html/1132.html" rel="external">"Unruptured intracranial aneurysms", section on 'Risk factors for aneurysm rupture'</a>.)</p><p>It is not known whether antithrombotic therapies influence the rate of rupture of intracranial aneurysms. By reducing thrombus formation in the aneurysmal sac, it is possible that antithrombotic therapy could <strong>increase</strong> rates of aneurysm rupture. Antithrombotic and antiplatelet therapies also could exacerbate the severity of the hemorrhage in case of rupture, perhaps even converting intramural or minor subarachnoid hemorrhages into major, life-threatening bleeding.</p><p>Conversely, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> could <strong>reduce</strong> the risk of rupture by inhibiting inflammatory mediators (such as matrix metalloproteinases and tumor necrosis factor-alpha) that might play a role in the evolution and eventual rupture of intracranial aneurysms [<a href="#rid3">3,4</a>]. Clinical data on these points are sparse, as summarized below.</p><p class="headingAnchor" id="H3"><span class="h1">EFFECT OF ANTIPLATELET THERAPY</span><span class="headingEndMark"> — </span>Available clinical data are limited and conflicting regarding the influence of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other antiplatelet agents on rates of aneurysm rupture. Overall, chronic use of antiplatelets appears safe and might even be protective in patients with unruptured, asymptomatic intracranial aneurysms. </p><p class="bulletIndent1"><span class="glyph">●</span>In the Nurses' Health Study, a large prospective longitudinal cohort study, middle-aged females who used &gt;15 <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> per week had twice the rate of all-cause subarachnoid hemorrhage compared with nonusers [<a href="#rid5">5</a>]. The excess risk was particularly pronounced among older and hypertensive females and was not observed among those taking lower doses of aspirin. In this study, there were an unduly large number of subarachnoid hemorrhages relative to ischemic strokes and intraparenchymal hemorrhages, although the fraction of subarachnoid hemorrhages that were due to ruptured aneurysms was not reported. Despite multivariate statistical adjustments, imbalances in other vascular risk factors between aspirin users versus nonusers in observational trials leave etiologic associations unproven.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use at least three times weekly was associated with a lower risk of aneurysm rupture in a nested case-control study of the untreated cohort of patients in the International Study of Unruptured Intracranial Aneurysms (ISUIA; adjusted odds ratio [OR] 0.27, 95% CI 0.11-0.67) [<a href="#rid3">3</a>]. Aspirin also prevented intracranial aneurysm rupture in an experimental mouse model [<a href="#rid6">6</a>] and this effect is thought to be mediated by cyclooxygenase-2 inhibition [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A nationwide case-control study in Denmark found that recent initiation of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, or both was associated with increased risk of subarachnoid hemorrhage [<a href="#rid8">8</a>]. However, this increased risk was restricted to the first three months after starting antiplatelet therapy and the assessment was based on relatively small numbers of patients. Risk of subarachnoid hemorrhage was not affected by longer-term use of antiplatelet agents. Meanwhile, a population-based Dutch case-control study found no association between use of antiplatelet agents and risk of subarachnoid hemorrhage [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with ischemic stroke, having an intracranial aneurysm did not result in excess risk of adverse outcomes related to antiplatelet therapy [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective case series of 362 patients, no cases of subarachnoid hemorrhage occurred despite pretreatment with dual antiplatelet therapy for three months before stent-assisted coiling or flow diversion of unruptured (often large) intracranial aneurysm [<a href="#rid11">11</a>].</p><p></p><p>Regarding the severity of subarachnoid hemorrhage, data from clinical case series have shown no apparent increase in the initial severity of bleeding and no adverse effect on long-term outcome in patients presenting with aneurysmal subarachnoid hemorrhage who were taking <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> prior to rupture [<a href="#rid12">12-14</a>]. In an analysis of the National Inpatient Sample including 11,549 patients with aneurysmal subarachnoid hemorrhage who were treated with surgical or endovascular aneurysm repair, aspirin use was not associated with in-hospital mortality but was associated with lower rates of cardiac complications and venous thromboembolic events. Furthermore, among patients treated with endovascular repair, the rate of poor outcomes was lower among aspirin users (32 versus 37 percent; OR 0.63, 95% CI 0.42-0.94) [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H4"><span class="h1">EFFECT OF ANTICOAGULATION</span><span class="headingEndMark"> — </span>No data supporting higher rupture rates following the use of anticoagulants are available from randomized clinical trials or large cohort studies. However, these studies do not convincingly exclude higher rates of aneurysmal subarachnoid hemorrhage in anticoagulated patients due to the infrequency of subarachnoid hemorrhage, which is typically combined with other causes of hemorrhagic strokes in reports of clinical trials. A population-based Dutch study noted an increased risk of subarachnoid hemorrhage in patients taking vitamin K antagonists on a case-crossover analysis (adjusted odds ratio [OR] 2.46, 95% CI 1.04-5.82), but the association was not significant on case-control and case-time-control analyses [<a href="#rid9">9</a>]. A Danish nationwide case-control study found an association between short-term (less than one month) of vitamin K antagonists and subarachnoid hemorrhage, but the association was not sustained with longer-term use of these drugs [<a href="#rid8">8</a>]. Among patients with ischemic stroke, presence of an intracranial aneurysm did not contribute to excess risk of adverse outcomes related to anticoagulation [<a href="#rid10">10</a>].</p><p>Anticoagulation might worsen the clinical outcome of aneurysmal subarachnoid hemorrhage. Death or dependency following aneurysmal subarachnoid hemorrhage occurred in 93 percent (14 of 15) of anticoagulated patients versus 49 percent of those not receiving anticoagulants in one reported case series [<a href="#rid16">16</a>]. This was due to the worse clinical status at the time of admission of anticoagulated patients as a consequence of more severe initial bleeding. A study using a large registry of hospitalized patients in the United States (the National Inpatient Sample) found that anticoagulated patients had higher crude rates of in-hospital mortality (19 versus 13 percent) and poor outcome (54 versus 38 percent), but both of these findings were <strong>not</strong> significant on multivariable analysis [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1467006596"><span class="h1">EFFECT OF THROMBOLYSIS</span><span class="headingEndMark"> — </span>Limited data suggest that intravenous thrombolysis with recombinant tissue plasminogen activator (tPA) appears safe in patients with unruptured intracranial aneurysms who have an acute ischemic stroke [<a href="#rid17">17,18</a>]. This argues against an increased risk of rupture from the use of drugs that affect coagulation.</p><p class="headingAnchor" id="H5"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>American Heart Association guidelines [<a href="#rid19">19,20</a>] and major reviews [<a href="#rid21">21</a>] concerning management of unruptured intracranial aneurysms do not address the use of antiplatelet agents or anticoagulants. Given the available information as summarized above, it is not clear that antithrombotic therapies increase the risk of aneurysm rupture. However, the following observations have been made:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> does not appear to be associated with worse clinical outcomes from aneurysmal subarachnoid hemorrhage, but the existing data are meager (see <a class="local">'Effect of antiplatelet therapy'</a> above). Consequently, at present, detection of an unruptured intracerebral aneurysm should not be regarded as a contraindication to antiplatelet therapy for patients who have a clear indication for such medication. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited data suggest that anticoagulation with oral vitamin K inhibitors might worsen the severity of initial bleeding if rupture does occur (see <a class="local">'Effect of anticoagulation'</a> above). The potentially higher rates of death or disability observed after rupture of an intracranial aneurysm in patients taking anticoagulants should be considered in weighing the benefits versus risks of anticoagulation in patients known to harbor an unruptured intracranial aneurysm.</p><p></p><p>As an example, for an older adult patient with atrial fibrillation and prior stroke or transient ischemic attack who has a 10 mm unruptured aneurysm involving the anterior communicating artery, treatment with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> would be expected to produce an absolute reduction in the rate of stroke of approximately 6 percent per year (half of which are likely to be fatal or disabling) [<a href="#rid22">22</a>] but would augment the risk of fatal or disabling subarachnoid hemorrhage by approximately 0.25 percent per year [<a href="#rid2">2,16</a>]. In the absence of other risks, this analysis would lead one to favor anticoagulation in this particular patient.</p><p>For those patients with larger aneurysms or those whose absolute benefits from anticoagulation are smaller, the estimated harm from anticoagulation may substantially mitigate its benefits. Thus, the decision must be individualized according to the best estimates of benefits versus risks.</p><p>It is unclear how the need for chronic anticoagulation should influence the complex benefit/risk equation regarding repair of unruptured intracranial aneurysms [<a href="#rid16">16,23,24</a>]. Anticoagulation without aneurysm repair is reasonable for patients with a solid indication for anticoagulation who have aneurysms with a low estimated risk of rupture. For patients with aneurysms at higher risk of rupture, and those for whom the absolute benefits from anticoagulation are deemed smaller, the decision regarding the use of anticoagulation must be individualized according to the best estimates of benefits versus risks, accounting for patient values and preferences. Most experts do not consider a requirement for anticoagulation therapy to be an indication for aneurysm repair [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H1156107036"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">"Society guideline links: Stroke in adults"</a>.)</p><p class="headingAnchor" id="H7908451"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and complications of intracranial aneurysms</strong> – Unruptured intracranial aneurysms are detected in 2 to 3 percent of older adults. Subarachnoid hemorrhage from a ruptured intracranial aneurysm is associated with high morbidity and mortality. (See  <a class="medical medical_review" href="/z/d/html/1132.html" rel="external">"Unruptured intracranial aneurysms"</a> and  <a class="medical medical_review" href="/z/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiplatelet therapy</strong> – Based upon limited evidence, daily use of regular doses of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> appears to be safe and there is preliminary evidence that it might even decrease the risk of aneurysm rupture. The risks associated with other antiplatelet agents or with combination of antiplatelet agents are not known. (See <a class="local">'Effect of antiplatelet therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation</strong> – Anticoagulation may exacerbate the degree of hemorrhage in case of rupture and may worsen the clinical outcome of aneurysmal subarachnoid hemorrhage. (See <a class="local">'Effect of anticoagulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individualized management</strong> – Management of a patient with an unruptured intracranial aneurysm who requires treatment with an antiplatelet agent or anticoagulation for another indication requires careful evaluation of multiple factors. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General principles</strong> – Two general principles apply to these patients (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Detection of an unruptured intracerebral aneurysm should not be regarded as a contraindication to antiplatelet therapy for patients who have a clear indication for such medication.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anticoagulation without treatment of the aneurysm is reasonable for patients with a solid indication for anticoagulation who have aneurysms with a low estimated risk of rupture. For patients with aneurysms at higher risk of rupture, and those for whom the absolute benefits from anticoagulation are deemed smaller, the decision regarding the use of anticoagulation must be individualized according to the best estimates of benefits versus risks, accounting for patient values and preferences.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessment of individual risks</strong> – Factors to be considered include the following (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Risk of spontaneous rupture of the aneurysm (eg, size, location)</p><p class="bulletIndent3"><span class="glyph">-</span>Risk of thrombosis/stroke if antiplatelet/anticoagulant treatment is not given</p><p class="bulletIndent3"><span class="glyph">-</span>Risk of exacerbated bleeding from an aneurysmal rupture if anticoagulant treatment is given</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wermer MJ, van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis. Stroke 2007; 38:1404.</a></li><li><a class="nounderline abstract_t">Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 2003; 362:103.</a></li><li><a class="nounderline abstract_t">Hasan DM, Mahaney KB, Brown RD Jr, et al. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011; 42:3156.</a></li><li><a class="nounderline abstract_t">Vergouwen MD, Rinkel GJ, Algra A, et al. Prospective Randomized Open-label Trial to evaluate risk faCTor management in patients with Unruptured intracranial aneurysms: Study protocol. Int J Stroke 2018; 13:992.</a></li><li><a class="nounderline abstract_t">Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999; 30:1764.</a></li><li><a class="nounderline abstract_t">Suzuki T, Kamio Y, Makino H, et al. Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model. Cerebrovasc Dis 2018; 45:180.</a></li><li><a class="nounderline abstract_t">Starke RM, Chalouhi N, Ding D, Hasan DM. Potential role of aspirin in the prevention of aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2015; 39:332.</a></li><li><a class="nounderline abstract_t">Pottegård A, García Rodríguez LA, Poulsen FR, et al. Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark. Thromb Haemost 2015; 114:1064.</a></li><li><a class="nounderline abstract_t">Risselada R, Straatman H, van Kooten F, et al. Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage. J Thromb Haemost 2011; 9:517.</a></li><li><a class="nounderline abstract_t">Shono Y, Sugimori H, Matsuo R, et al. Safety of antithrombotic therapy for patients with acute ischemic stroke harboring unruptured intracranial aneurysm. Int J Stroke 2018; 13:734.</a></li><li><a class="nounderline abstract_t">Peret A, Mine B, Bonnet T, et al. Safety and efficacy of a pre-treatment antiplatelet regimen of unruptured intracranial aneurysms: a single-center experience. Neuroradiology 2020; 62:1029.</a></li><li><a class="nounderline abstract_t">Juvela S. Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg 1995; 82:945.</a></li><li><a class="nounderline abstract_t">Toussaint LG 3rd, Friedman JA, Wijdicks EF, et al. Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. J Neurosurg 2004; 101:921.</a></li><li><a class="nounderline abstract_t">Al-Mufti F, Ogulnick J, Feldstein E, et al. Impact of pre-ictal antiplatelet therapy use in aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 2021; 211:107022.</a></li><li><a class="nounderline abstract_t">Dasenbrock HH, Yan SC, Gross BA, et al. The impact of aspirin and anticoagulant usage on outcomes after aneurysmal subarachnoid hemorrhage: a Nationwide Inpatient Sample analysis. J Neurosurg 2017; 126:537.</a></li><li><a class="nounderline abstract_t">Rinkel GJ, Prins NE, Algra A. Outcome of aneurysmal subarachnoid hemorrhage in patients on anticoagulant treatment. Stroke 1997; 28:6.</a></li><li><a class="nounderline abstract_t">Edwards NJ, Kamel H, Josephson SA. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature. Stroke 2012; 43:412.</a></li><li><a class="nounderline abstract_t">Chiu WT, Hong CT, Chi NF, et al. The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm. PLoS One 2017; 12:e0180021.</a></li><li><a class="nounderline abstract_t">Thompson BG, Brown RD Jr, Amin-Hanjani S, et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46:2368.</a></li><li><a class="nounderline abstract_t">Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke 2023; 54:e314.</a></li><li><a class="nounderline abstract_t">Brown RD Jr, Broderick JP. Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. Lancet Neurol 2014; 13:393.</a></li><li><a class="nounderline abstract_t">Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857.</a></li><li><a class="nounderline abstract_t">Wardlaw JM, White PM. The detection and management of unruptured intracranial aneurysms. Brain 2000; 123 ( Pt 2):205.</a></li><li><a class="nounderline abstract_t">White PM, Wardlaw J. Unruptured intracranial aneurysms: prospective data have arrived. Lancet 2003; 362:90.</a></li><li><a class="nounderline abstract_t">Etminan N, Beseoglu K, Barrow DL, et al. Multidisciplinary consensus on assessment of unruptured intracranial aneurysms: proposal of an international research group. Stroke 2014; 45:1523.</a></li></ol></div><div id="topicVersionRevision">Topic 1320 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332442" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867109" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21980208" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30019634" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prospective Randomized Open-label Trial to evaluate risk faCTor management in patients with Unruptured intracranial aneurysms: Study protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471421" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prospective study of aspirin use and risk of stroke in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29614486" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25967073" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Potential role of aspirin in the prevention of aneurysmal subarachnoid hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26202836" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21155965" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29543141" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Safety of antithrombotic therapy for patients with acute ischemic stroke harboring unruptured intracranial aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32170373" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Safety and efficacy of a pre-treatment antiplatelet regimen of unruptured intracranial aneurysms: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760196" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15597751" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34781219" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of pre-ictal antiplatelet therapy use in aneurysmal subarachnoid hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058205" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The impact of aspirin and anticoagulant usage on outcomes after aneurysmal subarachnoid hemorrhage: a Nationwide Inpatient Sample analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996479" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcome of aneurysmal subarachnoid hemorrhage in patients on anticoagulant treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156701" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28662192" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26089327" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37212182" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646873" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577005" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648430" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The detection and management of unruptured intracranial aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867103" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Unruptured intracranial aneurysms: prospective data have arrived.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668202" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multidisciplinary consensus on assessment of unruptured intracranial aneurysms: proposal of an international research group.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
